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The case of a 72-year-old male patient with HCC is presented in whom percutaneous RFA was used as the sole ﬁrst-line anticancer
treatment, since he denied having partial hepatectomy. The patient underwent RFA two more times, at 1.5 years for treating a local
tumorprogressionattheinitialablationsiteandat11yearsaftertheﬁrstsessionfortreatinganewremoteintrahepaticrecurrence.
He revealed a long-term survival of more than 12 years so far and still remains in excellent clinical status.
1.Introduction
Although surgical resection is the gold standard treatment of
HCC, only a limited number of HCC patients are surgical
candidates because of their lack of hepatic reserve, resulting
from coexisting advanced cirrhosis, widespread intrahepatic
involvement,andconcomitantdiseases[1].Furthermore,the
shortage of donors and the high cost of liver transplantation,
limit its use.
R F Ai saw i d e l ya c c e p t e da l t e r n a t i v et os u r g i c a lr e s e c t i o n
and plays a key role in the therapeutic management of early
stage HCC [2]. However, selecting the treatment modality to
suitindividual patientswithHCCremainsamatterofdebate
[3].
2. Case Presentation
A 72-year-old cirrhotic male patient, related to hepatitis C
virus infection, presented about 12 years ago with elevation
of a-fetoprotein (AFP) levels up to 110ng/mL during routine
laboratory tests. Computed tomography (CT) scan per-
formedatthattimedemonstratedahypodenselesion,4.5cm
in maximum diameter, located in the IVth segment of the
liver,withsignsofearlyarterialenhancementconsistentwith
HCC characteristics (Figure 1(a)). A biopsy was performed,
and the histopathological results conﬁrmed the diagnosis
of HCC. In view of the fact that the patient had only
a single lesion and was in functional grade A of Child-
Pugh classiﬁcation, he seemed to be a suitable candidate for
surgical resection. At the same time, since he was categorized
ashavingClassIICongestiveHeartfailurerelatedtoischemic
disease, he denied to undergo surgical treatment.
Taking into consideration the tumor’s size, location,
and morphology, RFA seemed to be the most appropriate
treatment. The whole procedure, which was performed
percutaneously at the CT-scan suite, was explained to him,
and an informed concept was obtained. The RFA was
performed under local anesthesia. Forty-ﬁve minutes before
the procedure, he received an analgesic and antidepressant
medication, consisting of 0,05gr pethidine hydrochloride
intramuscularly and 3mg bromazepam [Lexotanil Roche]
per os for better patient’s collaboration.
Initially, a preprocedure CT scan was obtained. A cool-
tip electrode was used [RADIONICS (Burlington, MA)] and
a pulsed RF energy was applied for 15min (Figure 1(b)).
After the ablation of the lesion was completed, a low pulse2 Case Reports in Medicine
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Figure 1: (a) A hypodense lesion with maximum diameter of
4.5cm located in the IVth segment of the liver (arrow), with signs
of early arterial enhancement, consistent with HCC characteristics.
(b) The tip of the electrode is seen inside the lesion during the ﬁrst
RFA session.
RF energy was applied for the ablation of the track. To
evaluate the immediate lesion’s response to the ablation, a
dual-phase dynamic contrast enhanced CT was performed
after the electrode removal. Follow up was performed at 1, 3,
and 6 months post-RFA and every 6 months afterwards.
The patient did not experience any pain, and the
postprocedural imaging ﬁndings revealed no enhancement.
AFP levels presented signiﬁcant reduction and ﬁnally nor-
malization two weeks later.
For a 18-month follow-up period the patient presented
excellent clinical status with normal levels of AFP and stable
appearance of the lesion on CT and magnetic resonance
imaging (MRI) scans, when a new rise of the AFP levels to
80ng/mL prompted us to repeat a new CT and MRI scan
(Figures 2(a) and 2(b)); the CT images shown depict the
local tumor progression as a slightly hypodense area adjacent
to the unenhanced area of the lesion corresponding to the
ablated site (short and long arrows, resp. on Figure 2(a)).
(a)
(b)
Figure 2: (a) After 18 months, a new CT scan depicted a local
tumor progression at the ablation site. Note the unenhanced area
of the lesion corresponding to the ablated site (long arrow) and the
local tumor progression seen as an adjacent hypodense area (short
arrow). (b) Similar to ﬁndings on the MRI scan, the ablated area
shows no signal (long arrow), whereas the local tumor progression
appears as a low signal area (short arrow).
Similar to the ﬁndings on the MRI scan (Figure 2(b)), the
ablated area shows no signal (long arrow), whereas the local
tumorprogressionappearsasalowsignalarea(shortarrow).
A second RFA session, following the same protocol, was
performed with technical success.
For a 9-year follow-up period the patient presented
excellent clinical status with normalization of AFP levels.
Moreover, the tumor’s maximum diameter decreased from
4.5cm to 0.5cm with well-deﬁned margins mimicking a
cystic formation on CT scans.
Nine and half years after the second RFA, a new remote
intrahepatic recurrence, located in the IInd segment of the
liver,wassuspectedbecauseofanotherincreaseofAFPvalues
to 74ng/mL during follow-up. RFA was once more the ther-
apeutic option. A multitined expandable electrode was used
[RITA StarBustTM XL electrosurgical device (RITA Medical
Systems, Inc, Mountain View, California) 2-3cm/15cm
length], and a pulsed RF energy was applied for 15min.Case Reports in Medicine 3
Table 1: Child-Pugh score.
Measure 1 point 2 points 3 points
Total bilirubin, µmol/l (mg/dl) <34 (<2) 34–50 (2-3) >50 (>3)
Serum albumin, g/l >35 28–35 <28
INR <1.7 1.71–2.20 > 2.20
Ascites None Mild Severe
Hepatic encephalopathy None Grade I-II Grade III-IV
(a)
(b)
Figure 3: Latest CT scan, 12 years after the initial RF procedure;
both lesions (arrows) are hardly visualized and might be misdiag-
nosed as cystic formations in the liver.
Table 2: Interpretation of the Child-Pugh score.
Points Class
5-6 A
7–9 B
10–15 C
Hypoattenuating, nonenhancing areas were observed during
both the arterial and portal venous phases, so the technique
was considered to be completed. Overall, 12 years after the
initial RF procedure, the patient was still alive with good
quality of life and no imaging ﬁndings or elevation of AFP
levels that may indicate a new recurrence. In the latest CT
scan, performed at the same period (12 years after the initial
RF procedure), both lesions were hardly visualized and could
have been misdiagnosed as cystic formations in the liver
(Figures 3(a) and 3(b)).
3. Discussion
Accurate tumor staging at diagnosis is crucial for the
therapeutic management of patients with HCC. According
to Barcelona-Clinic Liver Cancer classiﬁcation, patients at an
early stage are those who present asymptomatic single HCC
<5 c mo ru pt o3n o d u l e s<3cm. They will beneﬁt from
curative/eﬀective therapies: resection, liver transplantation,
and percutaneous ablation. In the case of single HCC <5
cm with signs of liver deﬁciency or in the case of 3 nodules
<3cm, RFA is the optimal treatment when other diseases
coexist [4].
Additionally, the Child-Pugh score is used to assess
the prognosis of cirrhosis, as well as the required strength
of treatment and the necessity of liver transplantation.
The score employs ﬁve clinical measures of liver disease.
Each measure is scored 1–3, with 3 indicating most severe
derangement (Table 1). Chronic liver disease is classiﬁed
into Child-Pugh class A to C, employing the added score
(Table 2).
The therapeutic results of RFA of hepatic tumors are
inﬂuenced by a variety of factors such as the skill of the
operator, the choice of technique, the generator power of the
RFA device, and the size, location, and morphology of the
tumor [5, 6].
RFA uses high temperatures aiming at the destruction
of the cancer cells. Alternating current through the tissue
creates friction on a molecular level. Increased intracellular
temperature generates localized interstitial heating. Tem-
peratures between 60–100◦C cause rapid denaturation and
coagulation of the cellular proteins. Moreover, RFA seems
to stimulate tumor-speciﬁc T lymphocytes and produce
expression of heat sock proteins activating the process of
apoptosis [7, 8]. Furthermore, the cool tip electrode allows
internal circulation of water, which cools the tissue adjacent
to the exposed electrode, maintaining low impedance during
the treatment cycle. Low impedance permits maximum
energy deposition for a larger ablation volume.
Despite of the eﬀectiveness of the technique, few reports
that include long-term survival rates have been published
[9–12]. In a large study consisting of 187 patients who4 Case Reports in Medicine
were excluded from surgery and who had Child A or B
cirrhosis, with either a single or multiple (as many as three)
HCCs, less than or equal to 3cm in diameter each, RFA
was the ﬁrst choice of treatment. The 3- and 5-year survival
rates of patients with Child A cirrhosis were 76% and 51%,
respectively, and for Child class B cirrhotic patients survival
rates were 46% at 3 years and 31% at 5 years [9].
Rossietal.[11]reported 1-,2-, 3-,4-, and5-yearsurvival
rates to be 94%, 86%, 68% 40%, and 40%, respectively.
Furthermore, Buscarini et al. [12]r e p o r t e da no v e r a l l
survival rate of 33% at 5 years. Disease-free survival at 5
years was 3%. Finally, Kim et al. [2] estimated 1-, 3-, and
5-year cumulative survival rates to be 95%, 64%, and 51%,
respectively. Five-year cumulative survival rates for patients
with HCC grade I, II and III were 71%, 44%, and 43%,
respectively, with no statistical signiﬁcance (P>. 05). Four-
yearcancer-freesurvivalratesingroups1,2,and3were39%,
10%, and 0%, respectively.
In our case although the overall survival could not have
been predicted 12 years ago, our decision is now proving
to have the most satisfactory result. At present, the ablated
t u m o r sa r ec y s t i ca n dh a v eas m a l ls i z e ,e v i d e n c eo fag o o d
response to RFA. During the 12 years period, the clinical
status of the patient remained and remains still excellent.
Summarizing, taking into consideration our patient’s
survival and the fact that he remains still alive with good
quality of life for a period of more than 12-years after the
initial RF procedure, we may suggest that percutaneous RFA
should be considered as an alternative means of treatment in
the long-term management of hepatocellular carcinoma.
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